荣昌生物(09995) - 2023 - 年度业绩

Supplemental Announcement to the 2022 Annual Report This announcement provides supplementary information to RemeGen Co., Ltd.'s 2022 annual report, detailing awards granted under H-share and A-share schemes and confirming the unchanged status of other annual report content Details of Awards Granted Under H-share Scheme This section details awards granted under the H-share scheme to directors, the five highest-paid individuals, and other employees, including grant quantities, purchase prices, vesting, and forfeiture Overview of H-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Purchase Price (HKD) | Vested During Reporting Period (Shares) | Forfeited During Reporting Period (Shares) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :------------------- | :-------------------------------------- | :-------------------------------------- | :------------------------------------ | | Executive Director | Fang Jianmin | 1,500,000 | 27.06 | 0 | 0 | 1,500,000 | | Executive Director | He Ruyi | 1,600,000 | 16.91 | 0 | 0 | 1,600,000 | | Five Highest-Paid Individuals | Subtotal | 500,000 | - | 137,500 | 212,500 | 150,000 | | Other Employees | Subtotal | 1,788,380 | - | 197,500 | 228,750 | 1,362,130 | - The exercise period for all H-share awards is eight years[2] Details of Awards Granted Under A-share Scheme This section provides specific information on awards granted under the A-share scheme to directors, senior management, major shareholders and their associates, and other employees, including grant quantities, grant prices, and vesting periods Overview of A-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Grant Price (RMB) | Average Closing Price Immediately Prior to Grant Date (RMB) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :---------------- | :---------------------------------------------------------- | :------------------------------------ | | Executive Director | Wang Weidong | 350,000 | 36.36 | 75.05 | 350,000 | | Executive Director | He Ruyi | 24,200 | 36.36 | 75.05 | 24,200 | | Executive Director | Lin Jian | 14,850 | 36.36 | 75.05 | 14,850 | | Other Senior Management, Major Shareholders & Employees | Subtotal | 2,480,400 | 36.36 | 75.05 | 2,465,550 | - All A-share awards were granted on December 28, 2022, with a vesting period extending to December 27, 2028[3] Other Information This section includes the announcement publication date and board composition as of that date, reaffirming that all other information and content of the 2022 annual report remain unchanged - This supplemental announcement was published on September 11, 2023[4] - As of the announcement date, the board of directors comprises 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors[4] - Except for the supplementary information disclosed in this announcement, all other information and content of the 2022 annual report remain unchanged[3]